curasan AG

euro adhoc: curasan AG
Curasan extends dental product range for US distribution
FDA grants 510(k) approval for Cerasorb® M Dental and Cerasorb® Perio

-------------------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. -------------------------------------------------------------------------------- 27.07.2005 curasan AG - specialists in regenerative medicine - today received 510(k) approval by the FDA for Cerasorb® M Dental and Cerasorb® Perio. Cerasorb® is a synthetic bone regeneration material that is fully resorbed by the body and replaced with autogenous bone. Cerasorb® M Dental is a second-generation product, featuring even faster resorption and bone replacement. It is used in regions exposed to lower loads and complements the classic Cerasorb®. In addition, the company has developed a product by the name of Cerasorb® Perio, which is designed specifically for bone defects caused by periodontitis. Thus, curasan has taken a major step forward in terms of developing indication-specific Cerasorb® products. "In autumn 2004, we introduced our own sales organisation for the US dental market. Cerasorb® M Dental and Cerasorb® Perio underline our ambitions as a leader within the field of state-of-the-art bone regeneration. Our target group will see the extension of our Cerasorb® portfolio as evidence of our commitment to the marketplace and will support our sales activities in this area," said curasan’s CEO H.D. Rössler. About curasan AG: curasan AG (ISIN: DE 000 549 453 8), an exchange-listed company, is a leading innovator within the growth market of bone and tissue regeneration. The company has developed a comprehensive product range centred around its synthetic bone regeneration material Cerasorb®, for use in soft and hard tissue. curasan AG's main goal is to occupy a leading position as a global specialist in Regenerative Medicine. For further information, please visit curasan’s corporate website at: end of announcement euro adhoc 27.07.2005 16:32:26 -------------------------------------------------------------------------------- ots Originaltext: curasan AG Im Internet recherchierbar: Further inquiry note: Dr. Erwin Amashaufer, curasan AG, Tel. 06027/46 86 465, eMail: Branche: Biotechnology ISIN: DE0005494538 WKN: 549453 Börsen: Frankfurter Wertpapierbörse Berliner Wertpapierbörse Hamburger Wertpapierbörse Baden-Württembergische Wertpapierbörse Börse Düsseldorf Niedersächsische Börse zu Hannover Bayerische Börse Bremer Wertpapierbörse (BWB)

Das könnte Sie auch interessieren: